The Institute for Clinical and Economic Review (ICER) has issued an evidence report on the effectiveness and value of 2 new calcitonin gene-related peptide monoclonal antibody treatments (CGRP mAbs) for migraine.1
Migraine is a disabling condition determined by both genetic and environmental factors. It affects an estimated 32 million people in the United States2 and produces a lifelong predisposition to develop severe headache and associated symptoms spontaneously or in response to triggers. Occasional migraine attacks usually are treated individually with symptomatic medications such as triptans. If attacks are frequent, regularly administered preventive treatment may decrease headache frequency or severity. A variety of US Food and Drug Administration–approved preventive treatments are available, including β-blockers such as propranolol, antiepileptic drugs such as topiramate, and biologics such as onabotulinumtoxinA. In general, these treatments provide modest relief of symptoms and some are poorly tolerated.3
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Loder E, Renthal W. Calcitonin Gene-Related Peptide Monoclonal Antibody Treatments for Migraine. JAMA Intern Med. 2019;179(3):421–422. doi:10.1001/jamainternmed.2018.7536
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: